Novavax Offers U.S. a Fourth Strong Covid-19 Vaccine

The company’s large U.S. trial found an efficacy rate of about 90 percent. But at this point, the nation is awash in other shots.

Novavax Offers U.S. a Fourth Strong Covid-19 Vaccine
The company’s large U.S. trial found an efficacy rate of about 90 percent. But at this point, the nation is awash in other shots.